Published in Vaccine Weekly, February 13th, 2002
Under the terms of the agreement, Lexigen will use PER.C6 for research and clinical development of therapeutics in the field of oncology. Crucell will receive upfront and annual payments, while Lexigen has an option for a commercial license. Further financial details were not disclosed.
According to Crucell's CEO Dinko Valerio, the deal strengthens the position of PER.C6 as the industry standard for the production of gene therapy and vaccine products. "An increasing number of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.